Brokers Offer Predictions for Tandem Diabetes Care, Inc.’s Q4 2025 Earnings (NASDAQ:TNDM)

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) – Equities research analysts at Leerink Partnrs boosted their Q4 2025 earnings estimates for shares of Tandem Diabetes Care in a research report issued on Friday, May 3rd. Leerink Partnrs analyst M. Kratky now anticipates that the medical device company will post earnings of $0.06 per share for the quarter, up from their previous forecast of $0.05. Leerink Partnrs currently has a “Outperform” rating on the stock. The consensus estimate for Tandem Diabetes Care’s current full-year earnings is ($1.62) per share.

Tandem Diabetes Care (NASDAQ:TNDM) last issued its quarterly earnings data on Wednesday, February 21st. The medical device company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). The business had revenue of $196.80 million during the quarter, compared to the consensus estimate of $204.86 million. Tandem Diabetes Care had a negative return on equity of 32.33% and a negative net margin of 18.37%.

A number of other equities research analysts have also recently issued reports on TNDM. Citigroup upped their price objective on shares of Tandem Diabetes Care from $31.00 to $38.00 and gave the stock a “neutral” rating in a report on Wednesday, April 3rd. Wells Fargo & Company upgraded shares of Tandem Diabetes Care from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $21.00 to $45.00 in a report on Monday, April 29th. Piper Sandler reiterated an “overweight” rating and issued a $50.00 price objective (up from $35.00) on shares of Tandem Diabetes Care in a report on Friday. SVB Leerink upgraded shares of Tandem Diabetes Care from a “market perform” rating to an “outperform” rating and upped their price objective for the stock from $34.00 to $45.00 in a report on Thursday, April 25th. Finally, Robert W. Baird upped their price target on shares of Tandem Diabetes Care from $28.00 to $36.00 and gave the company a “neutral” rating in a report on Friday. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, Tandem Diabetes Care has a consensus rating of “Moderate Buy” and a consensus price target of $44.50.

Tandem Diabetes Care Trading Up 22.3 %

Shares of NASDAQ:TNDM opened at $44.72 on Monday. The stock has a market capitalization of $2.89 billion, a PE ratio of -20.61 and a beta of 1.10. Tandem Diabetes Care has a 1 year low of $13.82 and a 1 year high of $47.00. The firm has a fifty day moving average price of $32.29 and a 200 day moving average price of $26.19. The company has a current ratio of 3.83, a quick ratio of 3.02 and a debt-to-equity ratio of 0.91.

Institutional Investors Weigh In On Tandem Diabetes Care

Institutional investors have recently added to or reduced their stakes in the company. Eminence Capital LP raised its stake in shares of Tandem Diabetes Care by 76.1% in the third quarter. Eminence Capital LP now owns 5,490,017 shares of the medical device company’s stock valued at $114,028,000 after purchasing an additional 2,372,458 shares in the last quarter. Jennison Associates LLC increased its holdings in Tandem Diabetes Care by 98.1% in the 1st quarter. Jennison Associates LLC now owns 2,556,124 shares of the medical device company’s stock valued at $90,512,000 after buying an additional 1,265,534 shares during the period. GW&K Investment Management LLC acquired a new position in shares of Tandem Diabetes Care in the 4th quarter valued at $36,288,000. Paradice Investment Management LLC lifted its holdings in shares of Tandem Diabetes Care by 23.9% during the 3rd quarter. Paradice Investment Management LLC now owns 1,520,065 shares of the medical device company’s stock worth $31,572,000 after acquiring an additional 293,250 shares during the period. Finally, Assenagon Asset Management S.A. acquired a new stake in shares of Tandem Diabetes Care during the 1st quarter valued at about $8,018,000.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.